Yuhan USA is actively searching for business development and strategic partnership opportunities

Yuhan USA is a global business development arm of Yuhan Corporation. We are exploring collaborative opportunities and seeking partnerships with global academic research centers, …

Yuhan USA is looking for potential therapeutic assets with validated proof-of-concept data for in-licensing. The company’s R&D focus areas are Oncology (targeted therapy, […] Yuhan …

RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. …

Feb 21, 2022 · Yuhan Corporation will make an investment of approximately 80 billion Won ($66.7M USD) towards the bio research center and CMC center project. Through the …

Sep 6, 2023 · Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy. Cyrus Therapeutics is a Korean biotechnology …

Jul 30, 2020 · Yuhan, which formerly led the Korean pharmaceutical industry with its sales force, has transformed itself into an innovative drug developer through investment in its R&D …

Apr 6, 2023 · Yuhan will invest a total of $23million through the acquisition of Progen’s old and new shares, thereby securing a 38.9% stake in Progen and becoming the sole largest …

Nov 24, 2021 · Yuhan Corporation (000100. KS) announced on the 17 th of November that the new drug candidate (YH25724) for the treatment of non-alcoholic steatohepatitis (NASH), …

Aug 6, 2020 · As an outpost of Yuhan’s globalization strategy, Yuhan USA is seeking new opportunities to expand its business domain through searching new drug materials and …